In the past few years, Glucagon-Like Peptide-1 (GLP-1) receptor agonists have gained significant popularity for medical management of type 2 diabetes mellitus, especially in patients with comorbid conditions. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.